查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1997341

臨床試驗影像市場：依服務類型、影像方式、最終使用者和治療領域分類－2026-2032年全球市場預測

Clinical Trial Imaging Market by Offerings, Modality, End-User, Therapeutic area - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，臨床試驗影像市場價值將達到 16.1 億美元，到 2026 年將成長到 17.2 億美元，到 2032 年將達到 28.3 億美元，複合年成長率為 8.42%。

主要市場統計數據
基準年 2025 16.1億美元
預計年份：2026年 17.2億美元
預測年份 2032 28.3億美元
複合年成長率 (%) 8.42%

簡要概述臨床試驗影像如何發展成為一項綜合策略功能，從而加快通訊協定決策並增強監管機構的信心。

臨床試驗影像已發展成為現代藥物研發的戰略支柱，它整合了先進的成像方式、分析技術和操作流程，以支持客觀終點、安全性監測和患者分層。近年來，影像已不再只是輔助測量工具，而是成為通訊協定設計、適應性試驗策略和監管溝通的關鍵要素。這種轉變既反映了影像擷取硬體的技術進步，也反映了能夠整合來自多個中心和供應商的異質影像資料集的軟體工具的同步發展。

技術融合、監管認可和不斷發展的營運模式如何重塑臨床試驗成像生態系統和決策流程。

臨床試驗影像領域正經歷一場變革，其驅動力包括技術融合、監管機構對客觀終點指標的重視以及不斷演進的營運模式。人工智慧 (AI) 和先進的分析技術透過提供自動分割、定量生物標記提取和異常檢測，對傳統的放射學評估進行了補充，從而降低了變異性並提高了對治療效果的敏感性。隨著這些功能的日益普及，申辦者和影像服務供應商正在採用混合工作流程，將自動預處理與盲法專家解讀相結合，以確保臨床有效性。

近期關稅調整對醫療影像專案的設備分配、供應商選擇和供應鏈彈性產生了影響，需要考慮實際因素和營運調整。

近期某些地區針對醫療設備、組件及相關服務徵收的關稅，為臨床試驗影像服務帶來了新的考量，尤其是在依賴跨境運輸掃描儀、配件和專用硬體的全球性試驗中。關稅帶來的成本壓力會影響設備採購時機、維護計畫以及現場服務與集中服務的選擇。實際上，申辦者和影像服務供應商正在權衡各種方案，例如本地採購設備、將影像解讀外包給區域核心檢查室，或利用雲端分析來最大限度地減少實體運輸。

基於細分的詳細洞察，使產品和服務、成像方式、治療重點和最終用戶期望與營運和臨床要求保持一致。

以細分市場為重點的分析揭示了產品和服務、成像方式、治療領域和最終用戶類別中清晰的優先事項和營運需求。基於產品和服務，市場研究團隊將市場分為「服務」和「軟體」兩大類，「服務」進一步細分為「影像操作服務」、「影像解讀和分析服務」、「系統和技術支援服務」以及「臨床實驗設計和諮詢服務」。這種細分凸顯了客戶通常會購買捆綁式服務模式，將現場支援和集中分析相結合，以確保其全球各地服務的一致性。基於影像方式，研究範圍涵蓋電腦斷層掃描 (CT)、心臟超音波圖、磁振造影(MRI)、正子斷層掃描 (PET)、超音波和放射成像，每種影像方式都有其獨特的成像通訊協定、品管和分析需求，這些都會影響供應商的選擇和培訓要求。

主要全球區域的區域基礎設施、監管多樣性和營運能力對臨床試驗影像策略和實施的影響。

區域趨勢對診斷影像實踐、供應商生態系統和監管合作有顯著影響，在能力、基礎設施和合作網路方面呈現出明顯的區域格局。在美洲，先進的診斷影像基礎設施、眾多核心影像實驗室和廣泛應用的數位化工作流程為複雜的多中心臨床試驗提供了支援。然而，營運挑戰依然存在，包括地理距離、各中心能力差異以及在不同的臨床環境中實現嚴格標準化的必要性。因此，申辦方往往傾向於採用集中式影像判讀結合區域技術支援的模式，以平衡品質和物流。

競爭格局洞察顯示專業供應商、軟體創新者、核心實驗室和 CRO 聯盟如何為試驗建立差異化的端到端成像解決方案。

臨床試驗影像領域的競爭格局反映了專業服務供應商、軟體創新者、影像核心實驗室和整合供應商聯盟的整合，從而塑造了服務交付模式。領先的影像機構透過提供檢驗的影像解讀平台、特定模態的專業知識以及諮詢式試驗設計服務來脫穎而出，幫助申辦方將臨床假設轉化為可靠的影像終點。同時，提供可擴展分析、安全雲端儲存和符合監管要求的審計追蹤的軟體公司在多供應商合作和資料管治中扮演著日益重要的角色。

影像專案的領導者將互通性、檢驗的分析和早期通訊協定調整相結合，以實施可操作的策略措施，從而降低試驗風險並提高資料效用。

產業領導者應採取策略性方法，整合技術投資、嚴格的營運規範和合作夥伴關係，以提升臨床試驗影像計畫的有效性。首先，應優先考慮互通性，選擇支援標準化影像通訊協定和安全性、檢驗資料傳輸的平台和供應商。此類選擇可減少下游流程的差異，並有助於總結分析。其次，應引入自動化分析，以輔助專家解讀，利用已驗證的演算法加速預處理，標示品質問題，並維持最終終點判定的盲法性。

採用嚴謹的混合方法，結合相關人員訪談、二手證據整合和資料檢驗，以確保對診斷影像提供可靠且可操作的見解。

本研究採用混合方法，以確保研究的嚴謹性、可重複性和對決策者的相關性。該方法結合了對行業相關人員（包括影像科負責人、臨床運營負責人和科學顧問）的調查方法，以及對公開的監管指南、臨床試驗註冊數據、技術白皮書和同行評審文獻的全面二次分析。主要訪談著重於營運挑戰、供應商選擇標準、特定成像方式的考量以及區域實施瓶頸，從而為二次分析結果提供了實證觀點。

總結了綜合成像策略、檢驗的分析方法和操作彈性如何決定臨床試驗的成功和證據的可靠性。

臨床試驗影像已成為實證醫學的核心，它提供客觀且可重複的測量結果，為臨床決策和監管對話提供支援。先進成像技術、自動化分析和整合服務模式的結合，能夠提高終點敏感度、降低變異性並加快獲得有意義結果的速度。同時，影像技術異質性、區域差異以及不斷變化的業務需求所帶來的營運複雜性，也要求我們進行周密的規劃、供應商管治以及對可互操作系統進行投資。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 臨床試驗影像市場：依產品/服務分類

  • 服務
    • 影像處理操作服務
    • 影像分析服務
    • 系統和技術支援服務
    • 臨床實驗設計與諮詢服務
  • 軟體
  • 硬體

第9章 臨床試驗影像市場：依影像方式分類

  • 電腦斷層掃描
  • 心臟超音波圖
  • 磁振造影
  • 正子斷層掃描
  • 超音波
  • X光

第10章 臨床試驗影像市場：依最終使用者分類

  • 學術和政府附屬研究機構
  • 生技公司
  • 合約研究機構
  • 製藥公司

第11章 臨床試驗影像市場：依治療領域分類

  • 內分泌學
  • 免疫疾病
  • 感染疾病
  • 神經病學
  • 腫瘤學

第12章 臨床試驗影像市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 臨床試驗影像市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 臨床試驗影像市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國臨床試驗影像市場

第16章：中國臨床試驗影像市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Alimentiv Inc.
  • Anagram 4 Clinical Trials
  • Biospective Inc.
  • BioTelemetry, Inc.
  • Boston Imaging Core Lab LLC
  • Cardiovascular Imaging Technologies LLC
  • Clario
  • GE HealthCare Technologies Inc.
  • Icon PLC
  • Image Analysis Ltd
  • Image Core Lab Private Limited
  • Imaging Endpoints II LLC
  • Invicro, LLC
  • Ixico PLC
  • Median Technologies
  • Medical Metrics Inc. by Catalent, Inc.
  • Medidata by Dassault Systemes
  • Medpace, Inc.
  • Micron Inc.
  • Mint Medical GmbH
  • Navitas Life Sciences
  • Parexel International Corporation
  • Perceptive Informatics LLC
  • Perspectum Ltd
  • Prism Clinical Imaging, Inc.
  • ProScan Imaging LLC
  • Quotient Sciences Limited
  • Radiant Sage LLC
  • Resonance Health Ltd.
  • Voiant Clinical
  • WCG Clinical, Inc.
Product Code: MRR-501246435DF5

The Clinical Trial Imaging Market was valued at USD 1.61 billion in 2025 and is projected to grow to USD 1.72 billion in 2026, with a CAGR of 8.42%, reaching USD 2.83 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.61 billion
Estimated Year [2026] USD 1.72 billion
Forecast Year [2032] USD 2.83 billion
CAGR (%) 8.42%

A concise orientation to how clinical trial imaging has evolved into an integrated, strategic capability that accelerates protocol decisions and regulatory confidence

Clinical trial imaging has matured into a strategic pillar of contemporary drug development, integrating advanced modalities, analytics, and operational workflows to support objective endpoints, safety monitoring, and patient stratification. Over recent years, imaging has expanded beyond a supporting measurement to become a decisive element in protocol design, adaptive trial strategies, and regulatory interactions. This shift reflects both technological advancements in acquisition hardware and the parallel evolution of software tools capable of harmonizing heterogeneous imaging datasets across sites and vendors.

As a result, sponsors and trial operators increasingly prioritize imaging strategy at earlier stages of study planning. Cross-functional teams now coordinate imaging logistics, vendor selection, quality assurance, and data governance in tandem with biostatistics and clinical operations, thereby reducing rework and accelerating readouts. Consequently, a layered approach to imaging-encompassing modality selection, centralized reading paradigms, and integrated analytics-has emerged as best practice where reproducibility and interpretability are critical.

Transitioning from isolated imaging tasks to a unified imaging program requires deliberate change management, investment in vendor oversight, and the adoption of interoperable systems. When executed well, these investments yield more defensible endpoints, streamlined regulatory submissions, and enhanced confidence across stakeholder groups, including clinical investigators and regulatory reviewers. The remainder of this executive summary explores the forces reshaping the landscape, tariff implications, segmentation-driven insights, regional dynamics, competitive activity, actionable recommendations, methodological rigor, and an invitation to procure the full report for deeper guidance.

How converging technologies, regulatory acceptance, and evolving operational models are reshaping the clinical trial imaging ecosystem and decision pathways

The clinical trial imaging landscape is experiencing transformative shifts driven by technology convergence, regulatory emphasis on objective endpoints, and evolving operational models. Artificial intelligence and advanced analytics now complement traditional radiologic assessment by offering automated segmentation, quantitative biomarker extraction, and anomaly detection that decrease variability and enhance sensitivity to treatment effects. As these capabilities become more accessible, sponsors and imaging service providers are adopting hybrid workflows that blend automated pre-processing with blinded expert reads to maintain clinical validity.

Concurrently, regulatory authorities have signaled greater receptivity to imaging-derived endpoints when supported by standardized acquisition and validated analytic pipelines, prompting sponsors to embed imaging strategy earlier in the protocol lifecycle. This regulatory receptivity encourages investments in imaging core labs, centralized reading models, and rigorous quality assurance frameworks. Operationally, there is a pronounced movement toward vendor consolidation and platform unification to reduce complexity and improve data traceability across multi-center, global trials.

Finally, payer and health economics stakeholders increasingly evaluate the real-world applicability of imaging biomarkers, which is influencing endpoint selection and long-term evidence plans. Together, these shifts compel organizations to reassess capabilities, prioritize interoperable systems, and cultivate partnerships that accelerate deployment of robust imaging programs aligned to clinical and commercial objectives.

Practical considerations and operational adaptations driven by recent tariff adjustments that affect equipment flows, vendor selection, and supply chain resilience for imaging programs

The recent imposition of tariffs affecting medical equipment, components, and associated services in some jurisdictions has introduced new considerations for clinical trial imaging operations, particularly in global studies that rely on cross-border shipment of scanners, accessories, and specialized hardware. Tariff-related cost pressures can influence timing for equipment procurement, maintenance scheduling, and decisions around on-site versus centralized services. In practice, sponsors and imaging service organizations evaluate the trade-offs between procuring equipment locally, outsourcing imaging reads to regional core labs, or leveraging cloud-hosted analytics to minimize physical transfers.

In response, many stakeholders have explored localized sourcing strategies and negotiated longer-term service agreements to stabilize total cost of ownership while preserving data quality and regulatory compliance. This strategy reduces the frequency of cross-border movements of capital equipment and emphasizes partnerships with regional vendors that can provide timely technical support and adherence to standardized acquisition protocols. Moreover, shifts in supply chain routing have encouraged closer collaboration between procurement, clinical operations, and vendor management teams to ensure continuity of imaging capacity for ongoing trials.

Importantly, organizations are also reviewing contracting terms to include tariff contingency clauses and flexible service-level agreements that account for potential trade disruptions. While tariff measures introduce complexity, they also motivate more resilient operational planning, diversified supplier networks, and greater emphasis on in-region capabilities that can safeguard trial timelines and data integrity.

Detailed segmentation-driven insights that align product/service offerings, imaging modalities, therapeutic priorities, and end-user expectations to operational and clinical requirements

Segment-focused analysis reveals distinct priorities and operational requirements across the product and service continuum, modalities, therapeutic areas, and end-user categories. Based on Product & Service, market study groups Services and Software, where Services is further clarified into Operational Imaging Services, Read Analysis Services, System & Technical Support Services, and Trial Design & Consulting Services; this segmentation highlights that clients often purchase bundled service models that combine hands-on site support with centralized analytics to maintain consistency across global sites. Based on Modality, the landscape encompasses Computed Tomography, Echocardiography, Magnetic Resonance Imaging, Positron Emission Tomography, Ultrasound, and X-Ray, each modality presenting unique acquisition protocols, quality controls, and analytic needs that affect vendor selection and training requirements.

Therapeutic nuance matters as well; based on Therapeutic area, studies span Endocrinology, Immunological Disorder, Infectious Diseases, Neurology, and Oncology, with oncology trials frequently demanding multi-parametric imaging and longer follow-up while neurology trials emphasize standardized cognitive and structural imaging endpoints. Based on End-User, the ecosystem includes Academic & Government Research Institutes, Biotechnology Companies, Contract Research Organizations, and Pharmaceutical Companies, where each end-user brings its own procurement cadence, regulatory expectations, and appetite for innovation. For instance, academic centers may prioritize methodological rigor and novel biomarkers, whereas commercial sponsors often emphasize scalability, cost predictability, and time to readout.

Taken together, these segmentation vectors underscore the importance of flexible service architectures, modality-specific standard operating procedures, and targeted client engagement models that align technical capabilities with therapeutic intent and end-user requirements. Strategic vendors and sponsors that tailor their offerings across these dimensions achieve higher operational efficiency and better alignment with trial goals.

How regional infrastructure, regulatory diversity, and operational capacity across major global regions influence clinical trial imaging strategy and execution

Regional dynamics exert a material influence on imaging operations, vendor ecosystems, and regulatory interactions, with distinct regional patterns in capacity, infrastructure, and collaborative networks. In the Americas, advanced imaging infrastructure, a large base of imaging core laboratories, and high adoption of digital workflows support complex, multi-center trials; however, operational challenges include geographic distances, variable site capabilities, and the need for robust standardization across heterogeneous clinical settings. Consequently, sponsors often favor centralized reading combined with regional technical support to balance quality and logistics.

In Europe, Middle East & Africa, regulatory diversity and variable imaging infrastructure necessitate meticulous harmonization of protocols, translation of standard operating procedures across languages, and careful site qualification processes. The region benefits from strong academic centers and established collaborative research networks, which facilitate multi-country studies if sponsors invest in upfront training and platform interoperability. In addition, regional vendors often provide valuable localized technical support and faster equipment deployment timelines.

In Asia-Pacific, rapid investments in imaging hardware, expanding clinical research capacity, and growing local CRO capabilities have increased the region's appeal for large-scale trials. Nevertheless, differences in clinical practice patterns, data protection frameworks, and modality penetration require tailored imaging strategies that emphasize early site assessment and scalable cloud-based solutions. Across all regions, success depends on proactive local engagement, standardized acquisition protocols, and robust QA programs that bridge regional variability and preserve data integrity for pooled analyses.

Competitive landscape insights showing how specialized providers, software innovators, core labs, and CRO alliances create differentiated end-to-end imaging solutions for trials

Competitive dynamics in clinical trial imaging reflect a blend of specialized service providers, software innovators, imaging core labs, and integrated vendor alliances that together shape service delivery models. Leading imaging organizations differentiate by offering validated reading platforms, modality-specific expertise, and consultative trial design services that help sponsors translate clinical hypotheses into robust imaging endpoints. At the same time, software companies that deliver scalable analytics, secure cloud storage, and regulatory-grade audit trails are increasingly central to multi-vendor orchestration and data governance.

Partnerships between imaging services and technology firms are common, enabling an end-to-end proposition that combines site training, centralized reads, and advanced post-processing. Contract Research Organizations expand their portfolios by incorporating imaging capabilities either organically or through strategic alliances, thereby offering sponsors single-vendor solutions that streamline vendor management. Academic centers and specialty research institutes continue to contribute methodological innovation and validation studies that inform best practices and regulatory dialogue.

For purchasers, competitive evaluation should prioritize demonstrated modality experience, validated analytic pipelines, regulatory compliance history, and the operational capacity to support global trials. Vendors that can demonstrate cross-modal interoperability, transparent quality metrics, and customizable service tiers generally hold a competitive edge. Ultimately, the market favors collaborators who can reduce complexity, provide traceable audit trails, and align technical delivery with clinical objectives.

Actionable strategic moves for imaging program leaders to integrate interoperability, validated analytics, and early protocol alignment to de-risk trials and enhance data utility

Industry leaders should adopt a strategic posture that integrates technological investment, operational rigor, and collaborative partnerships to elevate the effectiveness of clinical trial imaging programs. First, prioritize interoperability by selecting platforms and vendors that support standardized acquisition protocols and secure, auditable data transfer; such choices reduce downstream variability and facilitate pooled analyses. Second, incorporate automated analytics as a complement to expert reads, using validated algorithms to accelerate pre-processing and flag quality issues while preserving blinded adjudication for final endpoint determination.

Next, invest in early-stage imaging strategy development by embedding imaging experts in protocol design to align modality selection, timing of scans, and read paradigms with clinical endpoints and regulatory expectations. This approach minimizes rework and mitigates the risk of unreadable or unusable imaging data. Additionally, cultivate regional supplier networks and flexible contracting terms that account for tariff-related contingencies and localized equipment support, ensuring continuity of imaging capacity across diverse geographies. Finally, establish transparent quality metrics, regular cross-site calibration exercises, and governance mechanisms that assign clear accountability for imaging deliverables. By implementing these measures, sponsors and service providers can reduce operational friction, enhance data integrity, and accelerate the translational value of imaging within clinical programs.

A rigorous mixed-methods approach combining stakeholder interviews, secondary evidence synthesis, and data triangulation to ensure reliable and actionable imaging insights

This research employed a mixed-methods approach to ensure rigor, reproducibility, and relevance for decision-makers. The methodology combined primary qualitative engagement with industry stakeholders, including imaging directors, clinical operations leads, and scientific advisors, with comprehensive secondary analysis of publicly available regulatory guidance, clinical trial registries, technical white papers, and peer-reviewed literature. Primary interviews focused on operational challenges, vendor selection criteria, modality-specific considerations, and regional execution bottlenecks, providing grounded perspectives that contextualize secondary findings.

Data triangulation was applied throughout to validate themes and reconcile divergent viewpoints. The research team synthesized procedural standards, technical specifications, and real-world implementation lessons to produce actionable recommendations. Quality assurance procedures included cross-validation of interview transcripts, consistency checks across data sources, and peer review by domain experts to ensure the reliability of analytical conclusions. Where applicable, methodological caveats and assumptions were documented to help readers interpret findings in light of study scope and the evolving regulatory and technological environment.

Finally, the approach emphasized transparency in data provenance and interpretive steps, enabling readers to trace conclusions back to source inputs and understand how operational realities and technological innovations informed the analytic framework.

Concluding synthesis of how integrated imaging strategy, validated analytics, and operational resilience together determine trial success and evidence credibility

Clinical trial imaging now occupies a central role in the evidence generation pathway, offering objective, reproducible measures that support clinical decision-making and regulatory dialogue. The interplay of advanced modalities, automated analytics, and integrated service models creates opportunities to enhance endpoint sensitivity, reduce variability, and accelerate time to meaningful readouts. At the same time, operational complexity-driven by modality heterogeneity, regional differences, and evolving trade considerations-demands deliberate planning, vendor governance, and investment in interoperable systems.

Looking ahead, organizations that prioritize early integration of imaging strategy into protocol design, adopt validated analytics responsibly, and cultivate resilient supplier networks will be better positioned to harness imaging as a strategic differentiator. In parallel, rigorous quality assurance, transparent performance metrics, and close collaboration with regulatory and scientific stakeholders will remain essential to translating imaging data into credible clinical evidence. Collectively, these actions will strengthen the role of imaging across therapeutic areas and end-users, delivering clearer, more reliable outcomes for both clinical programs and broader health system stakeholders.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Clinical Trial Imaging Market, by Offerings

  • 8.1. Services
    • 8.1.1. Operational Imaging Services
    • 8.1.2. Read Analysis Services
    • 8.1.3. System & Technical Support Services
    • 8.1.4. Trial Design & Consulting Services
  • 8.2. Software
  • 8.3. Hardware

9. Clinical Trial Imaging Market, by Modality

  • 9.1. Computed Tomography
  • 9.2. Echocardiography
  • 9.3. Magnetic Resonance Imaging
  • 9.4. Positron Emission Tomography
  • 9.5. Ultrasound
  • 9.6. X-Ray

10. Clinical Trial Imaging Market, by End-User

  • 10.1. Academic & Government Research Institutes
  • 10.2. Biotechnology Companies
  • 10.3. Contract Research Organizations
  • 10.4. Pharmaceutical Companies

11. Clinical Trial Imaging Market, by Therapeutic area

  • 11.1. Endocrinology
  • 11.2. Immunological Disorder
  • 11.3. Infectious Diseases
  • 11.4. Neurology
  • 11.5. Oncology

12. Clinical Trial Imaging Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Clinical Trial Imaging Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Clinical Trial Imaging Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Clinical Trial Imaging Market

16. China Clinical Trial Imaging Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Alimentiv Inc.
  • 17.6. Anagram 4 Clinical Trials
  • 17.7. Biospective Inc.
  • 17.8. BioTelemetry, Inc.
  • 17.9. Boston Imaging Core Lab LLC
  • 17.10. Cardiovascular Imaging Technologies LLC
  • 17.11. Clario
  • 17.12. GE HealthCare Technologies Inc.
  • 17.13. Icon PLC
  • 17.14. Image Analysis Ltd
  • 17.15. Image Core Lab Private Limited
  • 17.16. Imaging Endpoints II LLC
  • 17.17. Invicro, LLC
  • 17.18. Ixico PLC
  • 17.19. Median Technologies
  • 17.20. Medical Metrics Inc. by Catalent, Inc.
  • 17.21. Medidata by Dassault Systemes
  • 17.22. Medpace, Inc.
  • 17.23. Micron Inc.
  • 17.24. Mint Medical GmbH
  • 17.25. Navitas Life Sciences
  • 17.26. Parexel International Corporation
  • 17.27. Perceptive Informatics LLC
  • 17.28. Perspectum Ltd
  • 17.29. Prism Clinical Imaging, Inc.
  • 17.30. ProScan Imaging LLC
  • 17.31. Quotient Sciences Limited
  • 17.32. Radiant Sage LLC
  • 17.33. Resonance Health Ltd.
  • 17.34. Voiant Clinical
  • 17.35. WCG Clinical, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CLINICAL TRIAL IMAGING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CLINICAL TRIAL IMAGING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY OFFERINGS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES CLINICAL TRIAL IMAGING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA CLINICAL TRIAL IMAGING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY OPERATIONAL IMAGING SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY OPERATIONAL IMAGING SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY OPERATIONAL IMAGING SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY READ ANALYSIS SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY READ ANALYSIS SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY READ ANALYSIS SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY SYSTEM & TECHNICAL SUPPORT SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY SYSTEM & TECHNICAL SUPPORT SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY SYSTEM & TECHNICAL SUPPORT SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY TRIAL DESIGN & CONSULTING SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY TRIAL DESIGN & CONSULTING SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY TRIAL DESIGN & CONSULTING SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY HARDWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY HARDWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY HARDWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY ECHOCARDIOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY ECHOCARDIOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY ECHOCARDIOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY ULTRASOUND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY ULTRASOUND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY ULTRASOUND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY X-RAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY X-RAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY X-RAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY ENDOCRINOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY ENDOCRINOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY ENDOCRINOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY IMMUNOLOGICAL DISORDER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY IMMUNOLOGICAL DISORDER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY IMMUNOLOGICAL DISORDER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS CLINICAL TRIAL IMAGING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS CLINICAL TRIAL IMAGING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA CLINICAL TRIAL IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA CLINICAL TRIAL IMAGING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA CLINICAL TRIAL IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA CLINICAL TRIAL IMAGING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE, MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE, MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE CLINICAL TRIAL IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE CLINICAL TRIAL IMAGING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 104. MIDDLE EAST CLINICAL TRIAL IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. MIDDLE EAST CLINICAL TRIAL IMAGING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 106. MIDDLE EAST CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 109. MIDDLE EAST CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 110. AFRICA CLINICAL TRIAL IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. AFRICA CLINICAL TRIAL IMAGING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 112. AFRICA CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 113. AFRICA CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 114. AFRICA CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 115. AFRICA CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC CLINICAL TRIAL IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC CLINICAL TRIAL IMAGING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. ASEAN CLINICAL TRIAL IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. ASEAN CLINICAL TRIAL IMAGING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 125. ASEAN CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 126. ASEAN CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 127. ASEAN CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 128. ASEAN CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 129. GCC CLINICAL TRIAL IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GCC CLINICAL TRIAL IMAGING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 131. GCC CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 132. GCC CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 133. GCC CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 134. GCC CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPEAN UNION CLINICAL TRIAL IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPEAN UNION CLINICAL TRIAL IMAGING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPEAN UNION CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPEAN UNION CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPEAN UNION CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPEAN UNION CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 141. BRICS CLINICAL TRIAL IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. BRICS CLINICAL TRIAL IMAGING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 143. BRICS CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 144. BRICS CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 145. BRICS CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 146. BRICS CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 147. G7 CLINICAL TRIAL IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. G7 CLINICAL TRIAL IMAGING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 149. G7 CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 150. G7 CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 151. G7 CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 152. G7 CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 153. NATO CLINICAL TRIAL IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. NATO CLINICAL TRIAL IMAGING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 155. NATO CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 156. NATO CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 157. NATO CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 158. NATO CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. UNITED STATES CLINICAL TRIAL IMAGING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 161. UNITED STATES CLINICAL TRIAL IMAGING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 162. UNITED STATES CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 163. UNITED STATES CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 164. UNITED STATES CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 165. UNITED STATES CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 166. CHINA CLINICAL TRIAL IMAGING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 167. CHINA CLINICAL TRIAL IMAGING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 168. CHINA CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 169. CHINA CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 170. CHINA CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 171. CHINA CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)